

# Aki Shiozawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2278302/publications.pdf>

Version: 2024-02-01

19  
papers

398  
citations

932766

10  
h-index

794141

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

614  
citing authors

#	ARTICLE	IF	CITATIONS
1	Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1300-1306.	1.2	5
2	A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. <i>Drugs and Aging</i> , 2021, 38, 1075-1085.	1.3	5
3	Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. <i>Neurourology and Urodynamics</i> , 2020, 39, 2206-2222.	0.8	8
4	Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case-€“Control Cohort Analysis. <i>Advances in Therapy</i> , 2020, 37, 4599-4613.	1.3	2
5	<p>Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 257-270.	0.7	1
6	Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data. <i>Neurodegenerative Disease Management</i> , 2018, 8, 97-103.	1.2	5
7	Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. <i>Journal of Rheumatology</i> , 2017, 44, 388-396.	1.0	111
8	Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. <i>Current Medical Research and Opinion</i> , 2017, 33, 117-124.	0.9	18
9	The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. <i>Clinical Therapeutics</i> , 2016, 38, 1710-1725.	1.1	6
10	Febuxostat in the management of gout: a cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2016, 19, 265-276.	1.0	9
11	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 411-418.	0.5	11
12	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care&nbsp;setting. <i>Patient Preference and Adherence</i> , 2015, 9, 971.	0.8	24
13	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 120.	1.6	52
14	Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. <i>BMJ Open</i> , 2015, 5, e007214.	0.8	22
15	Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study. <i>Current Medical Research and Opinion</i> , 2015, 31, 1611-1620.	0.9	2
16	Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat. <i>Postgraduate Medicine</i> , 2014, 126, 65-75.	0.9	20
17	Physician Adherence to ACR Gout Treatment Guidelines: Perception Versus Practice. <i>Postgraduate Medicine</i> , 2014, 126, 257-267.	0.9	28
18	An assessment of the impact of pregnancy on trauma mortality. <i>Surgery</i> , 2011, 149, 94-98.	1.0	35

#	ARTICLE	IF	CITATIONS
19	Cost of Inpatient Care and its Association with Hospital Competition. Journal of the American College of Surgeons, 2011, 212, 12-19.	0.2	32